Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...

Ozempic (semaglutide) and Mounjaro (tirzepatide) are brand-name solutions for subcutaneous injection. Doctors prescribe them to help manage blood sugar levels in people with type 2 diabetes.

Some weight loss injections include liraglutide, semaglutide, and tirzepatide. Weight loss injections involve a person injecting medications under their skin over a long period to aid weight loss.

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

Rybelsus is a GLP-1 agonist with semaglutide, like Ozempic and Wegovy, but it is taken as an oral pill rather than an injection. Who is it for? Rybelsus is approved for adults with type 2 ...